Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDX-301 + CDX-1140 + SBRT
- Development stage
- Phase 1
- Lead developer
- Celldex Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
CDX-301 + CDX-1140 + SBRT is a combination immunotherapy regimen being investigated for the treatment of advanced non-small cell lung cancer (NSCLC). The regimen consists of CDX-301 (a recombinant human Fms-like tyrosine kinase 3 ligand), CDX-1140 (an agonist monoclonal antibody targeting CD40), and stereotactic body radiotherapy (SBRT). CDX-301 acts as a potent hematopoietic growth factor that expands and mobilizes dendritic cells (DCs) in the blood and organs. CDX-1140 subsequently activates these DCs to enhance antigen presentation and anti-tumor immune responses. SBRT is employed to induce local tumor cell death and release tumor-associated antigens, potentially triggering an abscopal effect where systemic immune responses target distant metastatic sites. This therapeutic approach is being evaluated in clinical trials led by the Albert Einstein College of Medicine in collaboration with Celldex Therapeutics.
- Other names
- FLT3 ligandFLT-3 ligandFLT 3 ligandstereotactic body radiotherapyrhuFlt3LrhuFlt-3LrhuFlt 3Lrecombinant human Fms-like tyrosine kinase 3 ligand
02
Targets
CD40 (Cluster of differentiation 40 receptor)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on CDX-301 + CDX-1140 + SBRT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDX-301 + CDX-1140 + SBRT.